Skip to content

艾索基因

US · AXGN #2714 按市值排名 上市于 1970
34.62 -1.01 -2.83%
实时 - 追踪5344个代码 - 心跳于6秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 机构持股总比例下降了1.4个百分点。

机构持股

机构持股比例
99.20% -1.39pp
机构数量
303
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund69.27%
Hedge Fund17.96%
Public Company8.09%
Individual/Insider1.95%
Private Company1.72%
Government Pension Fund1.13%
Insurance Company0.56%
VC/PE Fund0.42%

主要股东 截至 2026-06-30

BlackRock 7.53% · 4.42M 股
Divisadero Street Capital Management, LP 6.79% · 3.98M 股
First Light Asset Management, LLC 4.68% · 2.75M 股
Vanguard Capital Management, LLC 4.49% · 2.64M 股
Morgan Stanley 4.49% · 2.64M 股
Polar Capital Holdings Plc 2.56% · 1.50M 股
Artemis Investment Management LLP 2.38% · 1.40M 股
Wellington Management Group 2.37% · 1.39M 股
Geode Capital Management, LLC 2.34% · 1.38M 股
Citadel Advisors LLC 2.32% · 1.36M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 29次买入 · 18次卖出

姓名职务持股比例
Erick DeVinney Vice President of Peripheral Nerve Science and Clinical Innovation 0.41%
Amy McBride-Wendell Lead Independent Director 0.18%
Doris Quackenbush Officer 0.16%
Jens Kemp Chief Marketing Officer 0.12%
Lindsey Hartley Chief Financial Officer 0.11%
Michael Dale Chief Executive Officer 0.11%
Alan Levine Independent Director 0.09%
Marc Began Executive VP, General Counsel & Chief Compliance Officer 0.09%
Paul Thomas Independent Director 0.06%
William Burke Independent Director 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-01 Joseph Tyndall Independent Director Automatic Disposition -3,500 $49.70
2026-08-10 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Sale -13,353 $14.85–48.42
2026-08-09 Marc Began Executive VP, General Counsel & Chief Compliance Officer Derivative Exercise and Sale -67,500 $8.16–47.35
2026-08-06 Kathy Weiler Director Automatic Disposition -14,150 $45.30
2026-06-23 Paul Thomas Independent Director Other Derivative Acquisition +5,579 --
2026-06-23 Amy McBride-Wendell Lead Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 John Johnson Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 Kathy Weiler Director Other Derivative Acquisition +4,392 --
2026-06-23 Alan Levine Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 William Burke Independent Director Other Derivative Acquisition +4,392 --
2026-06-23 Joseph Tyndall Independent Director Other Derivative Acquisition +4,392 --
2026-06-18 Paul Thomas Independent Director Derivative Exercise and Retained +18,867 --
2026-06-18 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 John Johnson Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 Kathy Weiler Director Derivative Exercise and Retained +14,150 --
2026-06-18 Alan Levine Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 William Burke Independent Director Derivative Exercise and Retained +14,150 --
2026-06-18 Joseph Tyndall Independent Director Derivative Exercise and Retained +14,150 --
2026-05-07 Amy McBride-Wendell Lead Independent Director Derivative Exercise and Sale -1,647 $14.85–42.60
2026-05-06 John Johnson Independent Director Derivative Exercise and Sale -11,050 $7.04–43.26

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

艾索基因 讨论区 0 条评论

发表评论